2017 Debates and Didactics in Hematology and Oncology
prIME Downloadable Slides
prIME Downloadable Slides

2017 Debates and Didactics in Hematology and Oncology

Not a member of My prIME? Join now for instant access.

Explore the latest updates in oncology and hematology with these downloadable slides from the annual Emory cancer conference presented July 26-30, 2017, in Sea Island, Georgia.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Aug 26, 2017

Expiration Date

Aug 26, 2018

Lung/Head & Neck/Lymphoma

Strategies for enhancing the efficacy of immunotherapy
Edmund Waller, MD, PhD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Are treatments for small-cell lung cancer getting better? – Yes
Suresh Ramalingam, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Are treatments for small-cell lung cancer getting better? – No
Taofeek Owonikoko, MD, PhD
Winship Cancer Center of Emory University, Atlanta, Georgia

Incorporating Immunotherapy into the treatment of non-small cell lung cancer (NSCLC)
Suresh Ramalingam, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

What is next for patients with stage III non-small cell lung cancer?
Walter J. Curran, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Management strategies for lung cancer sensitive or resistant to EGRF inhibitors
Conor Steuer, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Surgery is needed in the treatment of early-stage, human papillomavirus (HPV)-related oropharyngeal cancer – No
Jonathan Beitler, MD, MBA, FACR, FASTRO
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Surgery is needed in the treatment of early-stage, human papillomavirus (HPV)-related oropharyngeal cancer – Yes
Mihir Patel, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Immunotherapy for HNSCC in 2017
Nabil Saba, MD, FACP
Winship Cancer Center of Emory University, Atlanta, Georgia

Novel therapeutic approaches for saliva gland cancers
Conor Steuer, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Radiotherapy in favorable, early-stage Hodgkin lymphoma
James Armitage, MD, FASCO
University of  Nebraskas Medical Center, Omaha, Nebraska

Debate—Have we moved beyond EPOCH for B-cell non-Hodgkin lymphoma? – Yes
Christopher Flowers, MD, MS
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Have we moved beyond EPOCH for B-cell non-Hodgkin lymphoma? – No
Jonathon B. Cohen, MD, MS
Winship Cancer Center of Emory University, Atlanta, Georgia

T-cell Lymphomas: Diagnosis and new agents
Mary Jo Lechowicz, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Sequencing treatments in relapsed Hodgkin lymphoma
Leonard T. Heffner, Jr, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Marginal zone lymphomas: Current and future strategies
Jonathon Cohen, MD, MS
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Allogeneic transplant should be used as salvage therapy for relapsed diffuse large B-cell lymphoma (DLBCL) – Yes
Amelia Langston, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Allogeneic transplant should be used as salvage therapy for relapsed diffuse large B-cell lymphoma (DLBCL) – No
Jonathon B. Cohen, MD, MS
Winship Cancer Center of Emory University, Atlanta, Georgia

Back to Top

Gastrointestinal/Multiple Myeloma/Leukemia

Debate—Role of radiation in resectable and locally advanced pancreatic cancer – For
Pretesh Patel, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Role of radiation in resectable and locally advanced pancreatic cancer – Against
Bassel El-Rayes, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Immunotherapy in gastrointestinal (GI) malignancies
Oatunji Alese, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Colon cancer: Does side matter?
Christina Wu, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

New strategies in the management of hepatocellular carcinoma
Maria C. Russell, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Updates and best practices in the management of gastric cancer
Oatunji Alese, MD
Indiana University Simon Cancer Center, Indianapolis, Indiana

Debate—Optimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles – Yes
Bassel El-Rayes, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Optimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles – No
Christina Wu, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Antibodies are a standard part of first relapse management in multiple myeloma (MM)
Ajay K. Nooka, MD, MPH, FACP
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Antibodies are not the only standard part of first relapse management in multiple myeloma (MM)
Jonathan Kaufman, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

New targets and treatments for relapsed MM
Kenneth Anderson, MD
Harvard Medical School Dana-Farber Cancer Institute, Boston, Massachusetts

Initial therapy and transplant for MM
Sagar Lonial, MD, FACP
Winship Cancer Center of Emory University, Atlanta, Georgia

The value of myeloid mutation panels in patients with myeloproliferative neoplasms
Elliott Winton, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—All fit patients with acute myeloid leukemia (AML) should receive 7+3 as induction – No
Hagop Kantarjian, MD
The University of Texas, MD Anderson Cancer Center, Houston, Texas

Debate—All fit patients with acute myeloid leukemia (AML) should receive 7+3 as induction – Yes
Martha Arellano, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

New concepts in the management of elderly patients with AML
Martha Arellano, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Amyloidosis: What to do and how to diagnose, an update in 2017
Jonathan Kaufman, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

AML in 2017: The molecular therapeutic era finally arrives
William Blum, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

New treatments and combinations for relapsed chronic lymphocytic leukemia (CLL)
Susan O’Brien, MD
UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange, California

Back to Top

Breast/Melanoma/Other Hematology

Debate—Is complete axillary dissection needed following mastectomy and sentinel node biopsy? – Yes
Mylin Torres, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Is complete axillary dissection needed following mastectomy and sentinel node biopsy? – No
Preeti Subhedar, MD, MSPT
Winship Cancer Center of Emory University, Atlanta, Georgia

The role of molecular testing in tumor and blood for metastatic breast cancer
Jane Meisel, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Overcoming resistance to endocrine or HER2-directed therapy
Jane Meisel, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Triple-negative breast cancer: Subtyping and clinical implications
Keerthi Gogineni, MD, MSHP
Winship Cancer Center of Emory University, Atlanta, Georgia

Management of metastatic hormone receptor–positive breast cancer
Elisavet Paplomata, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Does complete node dissection for sentinel lymph node (SNL)–positive melanoma have a role? – Yes
Ragini Kudchadkar, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Does complete node dissection for sentinel lymph node (SNL)–positive melanoma have a role? – No
Michael Lowe, MD, MA
Winship Cancer Center of Emory University, Atlanta, Georgia

Update on immunotherapy in advanced melanoma
Ragini Kudchadkar, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Genomics and melanoma: Who to test and what to test for
Melinda Yushak, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Choosing and managing direct oral anticoagulants (DOACs)
Ana Antun, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Embarking on a thrombophila workup: Who, what, and when
Manila Gaddh, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

What do you need to know about transplant?
Amelia Langston, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Back to Top

Genitourinary/Other Tumor Types

Debate—Adjuvant tyrosine kinase inhibitor (TKI) should be given for high-risk renal cell carcinoma (RCC) after nephrectomy – Yes
Mehrdad Alemozaffar, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Debate—Adjuvant tyrosine kinase inhibitor (TKI) should be given for high-risk renal cell carcinoma (RCC) after nephrectomy – No
Mehmet Bilen, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Immune therapy and bladder cancer
Bradley Carthon, MD, PhD
Winship Cancer Center of Emory University, Atlanta, Georgia

Sequencing hormonal therapy and chemotherapy in prostate cancer
Mehmet Bilen, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Renal cell carcinoma: Systemic therapy—making sense of the present, predicting the future
Michael Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center, Washington DC

The evolving role of PARP inhibition in the management of ovarian cancer
Ira Horowitz, MD, SM, FACOG, FACS
Winship Cancer Center of Emory University, Atlanta, Georgia

Management of thyroid malignancies
Taofeek Owonikoko, MD, PhD
Winship Cancer Center of Emory University, Atlanta, Georgia

Immune and other new targets for brain tumors
Jeffrey J. Olson, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

New approaches for sarcoma management
Melinda Yushak, MD
Winship Cancer Center of Emory University, Atlanta, Georgia

Role and benefit of phase I trials: The Winship Experience
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Winship Cancer Center of Emory University, Atlanta, Georgia

Back to Top

After successful completion of this educational activity, participants should be able to:

  • Evaluate the risks and benefits of emerging therapies and novel treatment strategies for patients with solid tumor and hematologic malignancies, as well as the practical utility of these approaches based on recent clinical data
  • Apply best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care
  • Appropriately integrate multimodality therapy and multidisciplinary care to improve the management of patients with cancer

This educational activity is supported by grants from AbbVie Inc.; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Celgene Corporation; Lilly USA, LLC; and TESARO, Inc.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology and Winship Cancer Institute of Emory University.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Anderson has disclosed that he has received consulting fees for his role as advisor from Bristol-Myers Squibb, Gilead, Millennium, and Takeda. He also disclosed ownership interest as the scientific founder of C4 Therapeutics and OncoPep. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Arellano has disclosed that she has provided research support for Cephalon Oncology. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Armitage has disclosed that he has received consulting fees from Samus Therapeutics and Ziopharm. He has participated as a consultant on an independent data monitoring committee for Conatus. He is also on the board of directors for Tesaro Bio, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Atkins has disclosed that he has received consulting fees from Bristol-Myers Squibb, Exelixis, Genentech, Merck, Novartis, Pfizer, and X4 Pharmaceuticals.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Bilen has disclosed that he has received consulting fees from Exelixis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Blum has disclosed that he has received consulting fees from Astellas and Pfizer. He has also received research support from Boehringer Ingelheim. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cohen has disclosed that he has received consulting fees from AbbVie, Genentech, and Pharmacyclics. He has also performed contracted research for Bristol-Myers Squibb, Curis, Novartis, Seattle Genetics, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Curran has disclosed that he received consulting fees from AstraZeneca and Bristol-Myers Squibb. He also has ownership interest in NantHealth. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr El-Rayes has disclosed that he has received consulting fees from Astellas, BTG, and Merrimack. He has also performed contracted research for Boston Biomedical, Inc.; Bristol-Myers Squibb; Cleave Biosciences; Merck; Novartis; and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Flowers has disclosed that he has received consulting fees from AbbVie, Bayer, Celgene, Gilead Sciences, Optum Rx, Seattle Genetics, and Spectrum. He also disclosed receipt of research funding from AbbVie, Acerta, the Burroughs Wellcome Fund, Celgene, Gilead Sciences, Infinity Pharmaceuticals, Janssen Pharmaceuticals, Millennium/Takeda, Onyx Pharmaceuticals, Pharmacyclics, and  Spectrum. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Harvey has disclosed that he has received consulting fees from Bristol-Myers Squibb, Genentech, Huron, Spectrum, and Takeda. He has also performed contracted research for or received research support from Amgen, ArQule, AstraZeneca, Bristol-Myers Squibb, Boston Biomedical, Calithera, Celgene, Cleave, Genmab, Halozyme, Incyte, Medimmune, Merck, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kantarjian has disclosed that he has received consulting fees or honoraria from AbbVie, Actinium, Amgen, Ariad, Bristol-Myers Squibb, Immunogen, Orsinex, and Pfizer. In addition, Dr Kantarjian has received research funding from Amgen, Ariad, Astex, Bristol-Myers Squibb, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kaufman has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Seattle Genetics, and Sutro. He is also on a data monitoring committee for Pharmacyclics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kudchadkar has disclosed that she has received consulting fees from Bristol-Myers Squibb and Genentech. She has also performed contracted research for or received research support from Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lechowicz has disclosed that she has received consulting fees from Soligenix and Spectrum. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Lonial has disclosed that he has received consulting fees from Bristol-Myers Squibb, Celgene, Janssen, Merck, Millennium, Novartis, and Onyx. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Nooka has disclosed that he has received consulting fees from Onyx, Novartis, and Spectrum. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Olson has disclosed that he has performed contracted research for or received research support from Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Owonikoko has disclosed that he has received consulting fees from AbbVie and GI Therapeutics. He has also performed contracted research for or received research support from AbbVie, Bristol-Myers Squibb, Corvus, GI Therapeutics, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr O’Brien has disclosed that she has received consulting fees from AbbVie, Alexion, Amgen, Aptose Biosciences Inc, Astellas, Celgene, Gilead, GlaxoSmithKline, Janssen Oncology, Pfizer, Pharmacyclics, Sunesis, TG Therapeutics, and Vaniam Group LLC. She has also received research support from Acerta, Gilead, Pfizer, Pharmacyclics, ProNAI, Regeneron, and TG Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Mihir Patel has disclosed that he has received consulting fees from AstraZeneca. He has also performed contracted research for or received research support from AbbVie, AstraZeneca, and IRX Therapeutics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pillai has disclosed that she has received consulting fees from AstraZeneca. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ramalingam has disclosed that he has received consulting fees from AbbVie, Amgen, Ariad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Saba has disclosed that he has received consulting fees from Bristol-Myers Squibb. He has also performed contracted research for or received research support from Bristol-Myers Squibb and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Steuer has disclosed that he has received consulting fees from EMD Serono. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Waller has disclosed that he has received consulting fees from Novartis. He has also performed contract research for or received research support from Novartis.  He disclosed receipt of intellectual property rights/is a patent holder of Waller. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Winton has disclosed that he has received consulting fees from or performed contracted research for Gilead Sciences and Incyte Corporation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The following faculty members have no relevant financial relationships to disclose. They have agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation:

Dr Alemozaffar
Dr Alese
Dr Antun
Dr Beitler
Dr Carthon
Dr Gaddh
Dr Gogineni
Dr Heffner
Dr Horowitz
Dr Langston
Dr Lowe
Dr Meisel
Dr Paplomata
Dr Pretesh Patel
Dr Russell
Dr Subhedar
Dr Torres
Dr Wu
Dr Yushak

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.